NexImmune Inc. (NASDAQ: NEXI)
$3.87
+1.5000 ( +63.29% ) 34.5M
NexImmune Inc is a clinical-stage biotechnology company developing a novel approach to immunotherapy designed to employ the body's T cells to generate an antigen-specific cell-mediated immune response with curative potential for the patient. It creates therapies with curative potential for patients with cancer and other life-threatening immune-mediated diseases. The company has two product candidates in human trials: NEXI-001 in acute myeloid leukemia, or AML, and NEXI-002 in multiple myeloma, or MM.
Market Data
Open
$3.87
Previous close
$2.37
Volume
34.5M
Market cap
$4.09M
Day range
$2.20 - $6.90
52 week range
$1.25 - $28.69
SEC Fillings
Form Type | Description | Pages | Date |
---|---|---|---|
nt | Quarterly Reports | 1 | Mar 29, 2024 |
8-k | 8K-related | 22 | Feb 05, 2024 |
8-k | 8K-related | 14 | Feb 02, 2024 |
8-k | 8K-related | 14 | Feb 01, 2024 |
8-k | 8K-related | 12 | Jan 19, 2024 |
8-k | 8K-related | 12 | Dec 22, 2023 |
8-k | 8K-related | 12 | Dec 01, 2023 |
4 | Insider transactions | 1 | Nov 22, 2023 |
def | Proxies and info statements | 4 | Nov 20, 2023 |
8-k/a | 8K-related | 12 | Nov 20, 2023 |